NO20052991L - Kinazolinforbindelser. - Google Patents

Kinazolinforbindelser.

Info

Publication number
NO20052991L
NO20052991L NO20052991A NO20052991A NO20052991L NO 20052991 L NO20052991 L NO 20052991L NO 20052991 A NO20052991 A NO 20052991A NO 20052991 A NO20052991 A NO 20052991A NO 20052991 L NO20052991 L NO 20052991L
Authority
NO
Norway
Prior art keywords
quinazoline
therapy
formula
preparation
methods
Prior art date
Application number
NO20052991A
Other languages
English (en)
Other versions
NO20052991D0 (no
Inventor
Andrew Austen Mortlock
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20052991D0 publication Critical patent/NO20052991D0/no
Publication of NO20052991L publication Critical patent/NO20052991L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Kinazolinderivater med formel (I) hvor A er 5-leddet heteroaryl inneholdende et svovelatom og eventuelt inneholdende ett eller flere nitrogenatomer; preparater inneholdende dem, fremgangsmåter for deres fremstilling og anvendelse av dem i terapi.
NO20052991A 2002-12-24 2005-06-17 Kinazolinforbindelser. NO20052991L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02293239 2002-12-24
PCT/GB2003/005636 WO2004058752A1 (en) 2002-12-24 2003-12-22 Quinazoline compounds

Publications (2)

Publication Number Publication Date
NO20052991D0 NO20052991D0 (no) 2005-06-17
NO20052991L true NO20052991L (no) 2005-07-19

Family

ID=32668916

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052991A NO20052991L (no) 2002-12-24 2005-06-17 Kinazolinforbindelser.

Country Status (12)

Country Link
US (1) US7407946B2 (no)
EP (1) EP1575946A1 (no)
JP (1) JP2006516138A (no)
KR (1) KR20050087863A (no)
CN (1) CN1753889A (no)
AU (1) AU2003290322A1 (no)
BR (1) BR0317680A (no)
CA (1) CA2508921A1 (no)
MX (1) MXPA05006920A (no)
NO (1) NO20052991L (no)
WO (1) WO2004058752A1 (no)
ZA (1) ZA200504828B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83814C2 (ru) * 2002-12-24 2008-08-26 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
RU2005135337A (ru) 2003-04-16 2006-06-10 Астразенека Аб (Se) Производные хиназолина для лечения злокачественного новообразования
DE602004015108D1 (de) * 2003-06-02 2008-08-28 Astrazeneca Ab (3-((chinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
MX2007004403A (es) 2004-10-12 2007-04-27 Astrazeneca Ab Derivados de quinazolina.
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1785420A1 (en) * 2005-11-14 2007-05-16 4Sc Ag Thiazole analogues and uses thereof
US20090076075A1 (en) * 2006-03-02 2009-03-19 Frederic Henri Jung Quinoline derivatives
EP1994028A1 (en) * 2006-03-02 2008-11-26 AstraZeneca AB Quinoline derivatives for treating cancer
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2007113548A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
EP2149565A1 (de) 2008-07-24 2010-02-03 Bayer Schering Pharma AG Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
EP2558461B1 (en) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
US10222377B2 (en) * 2011-01-21 2019-03-05 Basilea Pharmaceutica Ag Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
EE200200119A (et) 1999-09-21 2003-04-15 Astrazeneca Ab Kinasoliini derivaadid ja nende kasutamine ravimitena
BR0111754A (pt) * 2000-06-28 2003-04-29 Astrazeneca Ab Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
ATE412657T1 (de) * 2002-12-24 2008-11-15 Astrazeneca Ab Therapeutische quinazolin-derivate
UA83814C2 (ru) * 2002-12-24 2008-08-26 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение

Also Published As

Publication number Publication date
ZA200504828B (en) 2008-02-27
KR20050087863A (ko) 2005-08-31
EP1575946A1 (en) 2005-09-21
AU2003290322A1 (en) 2004-07-22
NO20052991D0 (no) 2005-06-17
JP2006516138A (ja) 2006-06-22
CN1753889A (zh) 2006-03-29
US7407946B2 (en) 2008-08-05
CA2508921A1 (en) 2004-07-15
BR0317680A (pt) 2005-11-29
WO2004058752A1 (en) 2004-07-15
US20060058523A1 (en) 2006-03-16
MXPA05006920A (es) 2006-02-10

Similar Documents

Publication Publication Date Title
NO20052855L (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
ATE412657T1 (de) Therapeutische quinazolin-derivate
MXPA05006920A (es) Compuestos de quinazolina.
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
AU2910600A (en) Phenyl urea and phenyl thiourea derivatives
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
NO20053890L (no) Syntese av 4-amino-2-butenolklorider og anvendelse derav for fremstilling av 3-cyanokinoliner
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
NO20054195L (no) Isoksazolforbindelser som inhibitorer for varmesjokkproteiner
NO20082101L (no) Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
BR0207863A (pt) Inibidores piridìnicos de metaloproteinases da matriz
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
NO20004624D0 (no) Benzensulfonamid-derivater og deres anvendelse som medikamenter
BRPI0413467A (pt) aminopironas e seu uso como inibidoras da atm
DK0751930T3 (da) Amidinoderivater anvendelige som nitrogenoxid-synthase-inhibitorer
NO20070570L (no) Forbindelser.
DE60121461D1 (de) Kondensierte pyridoindolderivate
NO20062474L (no) Antivirale midler bestaende av diazaindol-dikarbonyl-piperazinyl
NO20044526L (no) Hemisterlinderivater og anvendelser derav
GB0308201D0 (en) Novel compounds
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
DK1095040T3 (da) Hidtil ukendte benzoxazoler med PDE-inhiberende aktivitet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application